NuCube Energy received a $25 million direct investment from the Alaska Industrial Development and Export Authority (AIDEA) to support the development of its NuSun™ microreactor platform. This state-backed funding will help NuCube advance manufacturing readiness, licensing, and deployment of carbon-free energy solutions, particularly benefiting remote Alaskan communities reliant on costly fossil fuels. The investment also supports NuCube's planned business combination with Launch Two Acquisition Corp., aiming for a Nasdaq listing. This partnership highlights growing interest in advanced nuclear technology for reliable, clean energy in challenging locations.
NuCube Energy's recent $25 million anchor investment from the Alaska Industrial Development and Export Authority provides context for energy sector interest. For readers following energy stocks, here is Pluang's market snapshot as of Oct 20, 2026 04:41 WIB: out of 79 priced US energy stocks, 29 rose and 49 fell. Notable movers include Liberty Energy Inc. Class A at USD 17.15 with a 3.31% increase, Energy Fuels Inc. at USD 8.19 down 3.31%, and TotalEnergies SE at USD 91.28 with a 3.15% rise but heavy sell activity at 98%.
Anteris Technologies received regulatory approval from Germany's BfArM to start enrolling patients in its global PARADIGM trial for the DurAVR Transcatheter Heart Valve. This approval allows the company to recruit patients at leading German centers, ...
XBiotech announced positive final efficacy results from its phase II TASKIN trial for vilamakitug (XB2001) in refractory metastatic colorectal cancer. The study, funded by the French National Cancer Institute, showed a 61.3% overall survival rate at ...
XBiotech announced positive final results from the Phase II TASKIN study, showing that adding Vilamakitug (XB2001) to standard chemotherapy improved 12-month overall survival to 61.3% in patients with refractory metastatic colorectal cancer, surpassi...
Nvidia announced a nearly $10 billion investment plan to support Europe's AI ecosystem, focusing on four German startups: Agile Robots, Avelios Medical, Mirelo, and Reflex Aerospace. This move aligns with Germany's goal to lead in industrial AI, with...
Recce Pharmaceuticals has reached a key milestone in its Phase 3 trial for treating diabetic foot infections with its RECCE® 327 Gel (R327G). An independent Data Monitoring Committee will review unblinded data from 75 patients, following encouraging ...
